Plaque-Derived FFRCT – the only FFRCT with Plaque Concordance – Coming Soon

Elucid Commences International PRE-VUE CCT Registry Study

Multi-center, Retrospective Trial to Assess Prognostic Accuracy of Elucid’s Plaque and Plaque-based FFRCT Software in Patients with Clinically Indicated CCTA SCCT2024, WASHINGTON, D.C., and BOSTON, July 18, 2024 – Elucid, a pioneering AI medical technology company...

Andrew Miller Joins Elucid as Chief Technology Officer

BOSTON, March 28, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead...